Probiotic escherichia coli nissle 1917 and commensal E. coli K12 differentially affect the inflammasome in intestinal epithelial cells

Digestion

Volumn 89, Issue 2, 2014, Pages 110-118

  Becker, Helen M ^a,b   Apladas, Aretussa ^a   Scharl, Michael ^a   Fried, Michael ^a   Rogler, Gerhard ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Crohn's disease; Escherichia coli Nissle 1917; Inflammasome

Indexed keywords

8 DIFLUOROMETHOXY 1 ETHYL 6 FLUORO 1,4 DIHYDRO 7 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 4 OXO 3 QUINOLINECARBOXYLIC ACID; CASPASE 3; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA CONVERTING ENZYME; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OCCLUDIN; PROBIOTIC AGENT; PROTEIN ZO1; CRYOPYRIN; PATTERN RECOGNITION RECEPTOR;

APOPTOSIS; ARTICLE; AUTOPHAGY; BACTERIAL OVERGROWTH; BACTERIAL STRAIN; CELL STIMULATION; CELL STRAIN CACO 2; CYTOKINE RELEASE; ENZYME ACTIVATION; ESCHERICHIA COLI; ESCHERICHIA COLI K 12; ESCHERICHIA COLI NISSLE 1917; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; LIMIT OF DETECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; ANIMAL CELL; CACO 2 CELL LINE; COMMENSAL ESCHERICHIA COLI; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOPRECIPITATION; INFLAMMATORY BOWEL DISEASE; PROTEIN EXPRESSION; ULCERATIVE COLITIS; WESTERN BLOTTING;

APOPTOSIS; AUTOPHAGY; CACO-2 CELLS; CARRIER PROTEINS; CASPASE 1; CASPASE 3; ENZYME ACTIVATION; EPITHELIAL CELLS; ESCHERICHIA COLI K12; HUMANS; INFLAMMASOMES; INTERLEUKIN-18; INTESTINAL MUCOSA; POLY(ADP-RIBOSE) POLYMERASES; PROBIOTICS;

EID: 84893655572     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000357521     Document Type: Article

References (47)

1. MacNaughton W: Mechanisms and Consequences of Intestinal Inflammation; in Johnson LR, Barret K, Gishan FK, Merchant JL, Said HM, Wood JD (ed): Physiology of the Gastrointestinal Tract. Amsterdam, Elsevier, 2005.
2. Lakatos PL: Environmental factors affecting inflammatory bowel disease: have we made progress? Dig Dis 2009; 27:215-225.
3. Petrof EO: Probiotics and gastrointestinal disease: clinical evidence and basic science. Antiinflamm Antiallergy Agents Med Chem 2009; 8:260-269.
4. Reid G, Sanders ME, Gaskins HR, Gibson GR, Mercenier A, Rastall R, Roberfroid M, Rowland I, Cherbut C, Klaenhammer TR: New scientific paradigms for probiotics and prebi-otics. J Clin Gastroenterol 2003; 37:105-118.
5. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, Kamm MA, Weismueller J, Be-glinger C, Stolte M, Wolff C, Schulze J: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53:1617-1623.
6. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M: Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11:853-858.
7. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354:635-639.
8. Sonnenborn U, Schulze J: The non-pathogenic Escherichia coli strain Nissle 1917-features of a versatile probiotic. Microb Ecol Health Dis 2009; 21:122-158.
9. Kamada N, Maeda K, Inoue N, Hisamatsu T, Okamoto S, Hong KS, Yamada T, Watanabe N, Tsuchimoto K, Ogata H, Hibi T: Non-pathogenic Escherichia coli strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells. Infect Immun 2008; 76:214-220.
10. Wehkamp J, Harder J, Wehkamp K, Weh-kamp-von Meissner B, Schlee M, Enders C, Sonnenborn U, Nuding S, Bengmark S, Fell-ermann K, Schroder JM, Stange EF: NF-kap-paB-and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004; 72: 5750-5758.
11. Schlee M, Wehkamp J, Altenhoefer A, Oel-schlaeger TA, Stange EF, Fellermann K: Induction of human beta-defensin 2 by the pro-biotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun 2007; 75: 2399-2407.
12. Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, Herrlinger KR, Stallmach A, Noack F, Fritz P, Schroder JM, Bevins CL, Fellermann K, Stange EF: NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004; 53: 1658-1664.
13. Wehkamp J, Harder J, Weichenthal M, Mueller O, Herrlinger KR, Fellermann K, Schro-eder JM, Stange EF: Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2003; 9:215-223.
14. Seo EJ, Weibel S, Wehkamp J, Oelschlaeger TA: Construction of recombinant E. coli Nissle 1917 (EcN) strains for the expression and secretion of defensins. Int J Med Micro-biol 2012; 302:276-287.
15. Zyrek AA, Cichon C, Helms S, Enders C, Son-nenborn U, Schmidt MA: Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Mi-crobiol 2007; 9:804-816.
16. Kamada N, Inoue N, Hisamatsu T, Okamoto S, Matsuoka K, Sato T, Chinen H, Hong KS, Yamada T, Suzuki Y, Suzuki T, Watanabe N, Tsuchimoto K, Hibi T: Nonpathogenic Esch-erichia coli strain Nissle1917 prevents murine acute and chronic colitis. Inflamm Bowel Dis 2005; 11:455-463.
17. Ukena SN, Singh A, Dringenberg U, Engel-hardt R, Seidler U, Hansen W, Bleich A, Brud-er D, Franzke A, Rogler G, Suerbaum S, Buer J, Gunzer F, Westendorf AM: Probiotic Esch-erichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2007; 2:e1308.
18. Boudeau J, Glasser AL, Julien S, Colombel JF, Darfeuille-Michaud A: Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther 2003; 18:45-56.
19. Altenhoefer A, Oswald S, Sonnenborn U, Enders C, Schulze J, Hacker J, Oelschlaeger TA: The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different entero-invasive bacterial pathogens. FEMS Immunol Med Microbiol 2004; 40:223-229.
20. Franchi L, Park JH, Shaw MH, Marina-Garcia N, Chen G, Kim YG, Nunez G: Intracellular NOD-like receptors in innate immunity, infection and disease. Cell Microbiol 2008; 10: 1-8.
21. Sutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberger GS, Grant EP, Bertin J, Coyle AJ, Galan JE, Askenase PW, Flavell RA: Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006; 24:317-327.
22. Eaton AD, Xu D, Garside P: Administration of exogenous interleukin-18 and interleu-kin-12 prevents the induction of oral tolerance. Immunology 2003; 108:196-203.
23. Allen IC, TeKippe EM, Woodford RM, Uron-is JM, Holl EK, Rogers AB, Herfarth HH, Jo-bin C, Ting JP: The NLRP3 inflammasome functions as a negative regulator of tumori-genesis during colitis-associated cancer. J Exp Med 2010; 207:1045-1056.
24. Hirota SA, Ng J, Lueng A, Khajah M, Parhar K, Li Y, Lam V, Potentier MS, Ng K, Bawa M, Mc-Cafferty DM, Rioux K P, Ghosh S, Xavier RJ, Colgan S P, Tschopp J, Muruve D, Macdonald JA, Beck PL: NLRP3 inflammasome plays a key role in the regulation of intestinal homeo-stasis. Inflamm Bowel Dis 2011; 17:1359-1372.
25. Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD: The NLRP3 in-flammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010; 32:379-391.
26. Siegmund B, Fantuzzi G, Rieder F, Gamboni-Robertson F, Lehr HA, Hartmann G, Dinarel-lo CA, Endres S, Eigler A: Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol 2001; 281:R1264-R1273.
27. Ten Hove T, Corbaz A, Amitai H, Aloni S, Belzer I, Graber P, Drillenburg P, van De-venter SJ, Chvatchko Y, Te Velde AA: Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. Gastroenterology 2001; 121:1372-1379.
28. Wiercinska-Drapalo A, Flisiak R, Jaroszewicz J, Prokopowicz D: Plasma interleukin-18 reflects severity of ulcerative colitis. World J Gastroenterol 2005; 11:605-608.
29. Ludwiczek O, Kaser A, Novick D, Dinarello CA, Rubinstein M, Tilg H: Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease. Eur Cytokine Netw 2005; 16:27-33.
30. Monteleone G, Trapasso F, Parrello T, Biancone L, Stella A, Iuliano R, Luzza F, Fusco A, Pallone F: Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 1999; 163: 143-147.
31. Pizarro TT, Michie MH, Bentz M, Wor-aratanadharm J, Smith MF Jr, Foley E, Mos-kaluk CA, Bickston SJ, Cominelli F: IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 1999; 162:6829-6835.
32. Villani AC, Lemire M, Fortin G, Louis E, Sil-verberg MS, Collette C, Baba N, Libioulle C, Belaiche J, Bitton A, Gaudet D, Cohen A, Langelier D, Fortin PR, Wither JE, Sarfati M, Rutgeerts P, Rioux JD, Vermeire S, Hudson TJ, Franchimont D: Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet 2009; 41:71-76.
33. Roberts RL, Topless RK, Phipps-Green AJ, Gearry RB, Barclay ML, Merriman TR: Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease. Genes Immun 2010; 11:351-356.
34. Di Sabatino A, Ciccocioppo R, Luinetti O, Ricevuti L, Morera R, Cifone MG, Solcia E, Corazza GR: Increased enterocyte apoptosis in inflamed areas of Crohn's disease. Dis Colon Rectum 2003; 46:1498-1507.
35. Turner JR: Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009; 9:799-809.
36. Guttsches AK, Loseke S, Zahringer U, Son-nenborn U, Enders C, Gatermann S, Bufe A: Anti-inflammatory modulation of immune response by probiotic Escherichia coli Nissle 1917 in human blood mononuclear cells. Innate Immun 2012; 18:204-216.
37. Baeuerlein A, Ackermann S, Parlesak A: Transepithelial activation of human leukocytes by probiotics and commensal bacteria: role of Enterobacteriaceae-type endotoxin. Microbiol Immunol 2009; 53:241-250.
38. Zeuthen LH, Fink LN, Metzdorff SB, Kris-tensen MB, Licht TR, Nellemann C, Frokiaer H: Lactobacillus acidophilus induces a slow but more sustained chemokine and cytokine response in naive foetal enterocytes compared to commensal Escherichia coli. BMC Immunol 2010; 11:2.
39. Zoumpopoulou G, Tsakalidou E, Dewulf J, Pot B, Grangette C: Differential crosstalk between epithelial cells, dendritic cells and bacteria in a co-culture model. Int J Food Micro-biol 2009; 131:40-51.
40. Adam E, Delbrassine L, Bouillot C, Reynders V, Mailleux AC, Muraille E, Jacquet A: Probi-otic Escherichia coli Nissle 1917 activates DC and prevents house dust mite allergy through a TLR4-dependent pathway. Eur J Immunol 2010; 40:1995-2005.
41. Hausmann M, Kiessling S, Mestermann S, Webb G, Spottl T, Andus T, Scholmerich J, Herfarth H, Ray K, Falk W, Rogler G: Tolllike receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 2002; 122:1987-2000.
42. Hafez M, Hayes K, Goldrick M, Grencis RK, Roberts IS: The K5 capsule of Escherichia coli strain Nissle 1917 is important in stimulating expression of Toll-like receptor 5, CD14, MyD88, and TRIF together with the induction of interleukin-8 expression via the mitogen-activated protein kinase pathway in epithelial cells. Infect Immun 2010; 78:2153-2162.
43. Tschopp J, Schroder K: NLRP3 inflamma-some activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 2010; 10:210-215.
44. Munoz-Planillo R, Franchi L, Miller LS, Nunez G: A critical role for hemolysins and bacterial lipoproteins in Staphylococcus au-reus-induced activation of the Nlrp3 inf lammasome. J Immunol 2009; 18 3: 3942-3948.
45. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J: Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science (New York) 2008; 320:674-677.
46. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-241.
47. Nazli A, Wang A, Steen O, Prescott D, Lu J, Perdue MH, Soderholm JD, Sherman PM, McKay DM: Enterocyte cytoskeleton changes are crucial for enhanced translocation of non-pathogenic Escherichia coli across metaboli-cally stressed gut epithelia. Infect Immun 2006; 74:192-201.